Enspryng has been approved by the Taiwan Food and Drug Administration for treating people 12 and older who have aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD), Chugai Pharmaceutical announced. The import drug license…
treatment
Recent Posts
- New antibody may explain mystery cases of NMOSD-like disease
- Are those mystery aches and pains due to NMOSD or regular life?
- NMOSD therapy linked to fewer attacks, less disability in Chinese study
- Where I go to recharge from the daily challenges of NMOSD
- Clinical trial data show NMOSD treatment reduces relapses